Alvogen launches new cancer generics in Romania; Mylan debuts Uroxatral copy in USA
US copy drugmaker Alvogen said last Friday that its subsidiary, Alvogen Romania, has launched generic versions of three oncology products in that market. The drugs to debut in Romania are:
• exemestane is an oral aromatase inhibitor, for early breast cancer in postmenopausal women. It is the generic equivalent of Pfizer’s Aromasin, and available in 25mg tablets;
• irinotecan (Irinotecan hydrochloride trihydrate), the generic equivalent of Pfizer’s Campto and is a cytostatic, a treatment for advanced colorectal cancer. The product is available in a 20mg/ml amber tubular glass vial; and
• letrozole, an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery in postmenopausal women. It is the generic equivalent of Novartis’ Femara, available in a carton box containing 30 film-coated tablets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze